[HTML][HTML] Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small …
PT Tan, MIA Aziz, F Pearce, WT Lim, DBC Wu, K Ng - BMC cancer, 2018 - Springer
Background Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and
is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker …
is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker …
Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatments for EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada
Objective The objective of this study was to compare the cost effectiveness of first-line
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
X Gu, Q Zhang, YB Chu, YY Zhao, YJ Zhang, D Kuo… - Lung Cancer, 2019 - Elsevier
Purpose Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are
becoming the standard treatments for Chinese patients with advanced non-small cell lung …
becoming the standard treatments for Chinese patients with advanced non-small cell lung …
Cost-effectiveness analysis of EGFR mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in China
R You, J Liu, DBC Wu, XY Qian, B Lyu… - Cancer management …, 2019 - Taylor & Francis
Objective The purpose of this study was to evaluate the cost-effectiveness of the combined
use of afatinib and epidermal growth factor receptor (EGFR) testing versus gemcitabine …
use of afatinib and epidermal growth factor receptor (EGFR) testing versus gemcitabine …
[HTML][HTML] Cost-effectiveness analysis of afatinib versus gefitinib for first-line treatment of advanced EGFR-mutated advanced non–small cell lung cancers
C Chouaid, L Luciani, K LeLay, P Do… - Journal of thoracic …, 2017 - Elsevier
Abstract Introduction The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib were compared in the multicenter, international …
tyrosine kinase inhibitor gefitinib were compared in the multicenter, international …
[HTML][HTML] Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
L Westerink, JLJ Nicolai, C Samuelsen… - The European Journal of …, 2020 - Springer
Background The therapeutic landscape for non-small-cell lung cancer (NSCLC) patients that
have common epidermal growth factor receptor (EGFR) mutations has changed radically in …
have common epidermal growth factor receptor (EGFR) mutations has changed radically in …
[HTML][HTML] EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong–A cost-effectiveness analysis
JHS You, WCS Cho, W Ming, Y Li, C Kwan, K Au… - PLoS …, 2021 - journals.plos.org
Introduction Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth factor
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …
[HTML][HTML] Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: analysis of real-world data in a tertiary hospital in Taiwan
SC Yang, WW Lai, JC Hsu, WC Su, JD Wang - PLoS One, 2020 - journals.plos.org
Introduction Comparison of the effectiveness and cost-effectiveness of three first-line EGFR-
tyrosine kinase inhibitors (TKIs) would improve patients' clinical benefits and save costs …
tyrosine kinase inhibitors (TKIs) would improve patients' clinical benefits and save costs …
Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France
M Pignata, C Chouaid, K Le Lay, L Luciani… - ClinicoEconomics …, 2017 - Taylor & Francis
Background and aims Lung cancer has the highest mortality rate of all cancers worldwide.
Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and has an …
Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and has an …
Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer
H Wang, C Zeng, X Li, Y Wang, X Li, W Ge - Future oncology, 2019 - Future Medicine
Aim: To evaluate the cost-utility of gefitinib and afatinib as first-line EGFR-mutated non-small-
cell lung cancer treatments from the Chinese healthcare system perspective. Materials & …
cell lung cancer treatments from the Chinese healthcare system perspective. Materials & …
相关搜索
- cost effectiveness lung cancer
- egfr mutations lung cancer
- cost effectiveness use of afatinib
- egfr mutations sequential treatment
- cost effectiveness egfr tyrosine
- cost effectiveness therapy for the treatment
- cost effectiveness mutation testing
- egfr mutations budget impact
- cost effectiveness gemcitabine cisplatin
- cost effectiveness kinase inhibitors
- cost effectiveness tertiary hospital
- use of afatinib lung cancer
- therapy for the treatment lung cancer
- gemcitabine cisplatin lung cancer
- budget impact lung cancer
- afatinib and gefitinib cost utility